A novel topical treatment combining three existing medications may offer improved results for people with pattern hair loss, or androgenetic alopecia, according to recent research. Hair thinning affects over 80% of men and nearly half of women at some point in their lives.
The new therapy, TH07, combines minoxidil and finasteride—the two FDA-approved hair loss treatments—with latanoprost, a drug used for glaucoma that also stimulates hair growth. Minoxidil promotes follicle activity, finasteride reduces DHT levels, and latanoprost is believed to enhance follicle stimulation.
In a six-month clinical study, more than half of men using TH07 reported dense hair regrowth, outperforming participants using the drugs individually. While results are encouraging, researchers caution that the trial was limited in size and duration. They emphasize that larger, long-term studies are needed to confirm the therapy’s effectiveness.
